Bio-Path Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPTH research report →
Companywww.biopathholdings.com
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
- CEO
- Vikram Paul Grover
- IPO
- 2008
- Employees
- 10
- HQ
- Bellaire, TX, US
Price Chart
Valuation
- Market Cap
- $248.50K
- P/E
- -0.04
- P/S
- 0.00
- P/B
- -0.03
- EV/EBITDA
- -0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 76.46%
- ROIC
- 67.66%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,674,000 · 12.33%
- EPS
- $-1.10 · 73.30%
- Op Income
- $-8,332,000
- FCF YoY
- 84.91%
Performance & Tape
- 52W High
- $0.23
- 52W Low
- $0.01
- 50D MA
- $0.06
- 200D MA
- $0.07
- Beta
- -0.28
- Avg Volume
- 23.72K
Get TickerSpark's AI analysis on BPTH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 30, 24 | Sherwood Aline | other | 2,000 |
| Jul 30, 24 | Aubert Paul | other | 2,000 |
| Jul 30, 24 | Cleaver Heath | other | 2,000 |
| Jul 30, 24 | MORRIS DOUGLAS P | other | 3,537 |
| Jul 30, 24 | Nielsen Peter Henry | other | 25,000 |
| May 2, 23 | Cleaver Heath | other | 10,000 |
| May 2, 23 | Aubert Paul | other | 10,000 |
| May 2, 23 | Sherwood Aline | other | 10,000 |
| May 2, 23 | MORRIS DOUGLAS P | other | 13,000 |
| May 2, 23 | Nielsen Peter Henry | other | 105,000 |
Our BPTH Coverage
We haven't published any research on BPTH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BPTH Report →